Cyclacel Pharmaceuticals (CYCC) Lifted to “Hold” at Zacks Investment Research

Cyclacel Pharmaceuticals (NASDAQ:CYCC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and cutaneous T-cell lymphoma. Seliciclib (CYC202 or R-roscovitine), a CDK inhibitor, is in Phase 2 for the treatment of lung cancer and nasopharyngeal cancer. “

CYCC has been the subject of a number of other research reports. ValuEngine upgraded Cyclacel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. HC Wainwright restated a “buy” rating on shares of Cyclacel Pharmaceuticals in a report on Thursday, March 29th.

NASDAQ CYCC traded down $0.02 on Wednesday, reaching $1.39. The company had a trading volume of 22,776 shares, compared to its average volume of 155,090. Cyclacel Pharmaceuticals has a 1 year low of $1.28 and a 1 year high of $4.56.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last released its quarterly earnings results on Monday, May 14th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.13) by $0.01. sell-side analysts forecast that Cyclacel Pharmaceuticals will post -0.43 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC purchased a new position in Cyclacel Pharmaceuticals in the 4th quarter worth approximately $108,000. Two Sigma Investments LP purchased a new position in shares of Cyclacel Pharmaceuticals during the 4th quarter valued at approximately $122,000. Finally, Virtu Financial LLC boosted its stake in shares of Cyclacel Pharmaceuticals by 69.5% during the 4th quarter. Virtu Financial LLC now owns 199,464 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 81,820 shares during the last quarter. Hedge funds and other institutional investors own 4.68% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes.

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.

Leave a Reply